Navigation Links
Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex
Date:3/10/2008

PRINCETON, N.J., TOKYO, and REDWOOD CITY, Calif., March 10 /PRNewswire-FirstCall/ -- Otsuka Pharmaceutical Co., Ltd. (OPC) and PDL BioPharma, Inc. (Nasdaq: PDLI) today announced the closing of the previously announced transaction under which Otsuka has acquired PDL's rights to IV Busulfex(R) (busulfan), including trademarks, patents, intellectual property and related assets, for $200 million plus inventory value.

IV Busulfex is an oncologic product marketed and sold in the United States (U.S.) and Canada, and through distributors in a number of other countries.

Now that this transaction has closed, OPC will oversee the outsourced manufacturing of the product, while its U.S. affiliate, Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), will investigate clinical studies for potential new indications for IV Busulfex. Another OPC affiliate, Otsuka America Pharmaceutical, Inc. (OAPI), will market the product for its current indication in the United States. OPDC was established in 2007 and OAPI was established in 1989 by Otsuka America, Inc. (OAI). Both OPDC and OAPI are wholly owned by OAI, which is the holding company for OPC's interests in the U.S. OAI is wholly owned by OPC.

INDICATION and IMPORTANT SAFETY INFORMATION

INDICATION:

IV Busulfex (busulfan) is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation (also referred to as blood or bone marrow transplantation or BMT) for chronic myelogenous leukemia (CML).

IMPORTANT SAFETY INFORMATION:

WARNING: Busulfex (busulfan) Injection is a potent cytotoxic drug that causes profound myelosuppression at the recommended dosage. It should be a
'/>"/>

SOURCE Otsuka Pharmaceutical Co., Ltd., and PDL BioPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... The Kidney Cancer Association (KCA) has established a CNN iReport ... News. , Bill Bro, KCA CEO, says, “We’re pleased ... international news organization. When we began using iReport last month, ... program highlights news of an enzyme that is lost in ... Kidney Cancer News also presents a report on outcomes from ...
(Date:7/30/2014)... 2014 Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... for the quarter ended June 30, 2014 on Wednesday, ... Regulus will host a conference call ... pm Eastern Daylight Time to discuss its second quarter ...
(Date:7/30/2014)... , July 30, 2014  Decision Resources ... and medical directors in the United ... of biosimilar market penetration will be the level ... (MCOs) and the expected lower cost to patients. ... biosimilars that meet their pricing expectations in order ...
(Date:7/30/2014)... , July 30, 2014  Replikins Ltd. today released ... the Ebola virus. Before the current outbreaks, the mean ... 100 amino acids) between 1995 and 2002 was 1.1; ... in 2012, and sixteen-fold in 2013, thus predicting the ... this technology has been shown to be able to ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... January 12 Bavarian Nordic,owns several United States ... core technology, MVA-BN(R), which is the basis for ... a vector for delivering,recombinant vaccines. Bavarian Nordic has ... infringement action. The claim in this case is ...
... ALAMEDA, Calif., Jan. 12 Singulex, Inc. today announced ... led by JAFCO Co., Ltd. and supported by existing ... round will support the commercialization of Singulex technologies in ... Hozoji, investment officer for JAFCO Life Science Investment, will ...
... Pharmaceuticals today,announced that it has achieved its first candidate ... GlaxoSmithKline. Anacor may,receive future milestone payments and royalties ... sales. , "We are pleased ... result of,the alliance we have built between our team ...
Cached Biology Technology:Bavarian Nordic's Case Against Oxford BioMedica 2Singulex Closes $19 Million Financing Round 2Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate 2
(Date:7/31/2014)... GAINESVILLE, Fla. --- By tracing nearly 3,000 genes ... moths, University of Florida scientists have created an ... to use large-scale, next-generation DNA sequencing. , ... more closely related to small moths than to ... how butterflies evolved. The study also found that ...
(Date:7/31/2014)... Latinos are the largest minority group in the United ... of Latinos are obese and are 1.2 times as ... , NYU College of Nursing student researcher Lauren Gerchow, ... factors that contribute to this problem by compiling a ... patterns in Latina women recently published in Nursing ...
(Date:7/31/2014)... known that biomass burning burning forests to ... , slash-and-burn agriculture and wildfires figures into ... until the release of a new study by ... Z. Jacobson, the degree of that contribution had ... in a paper published July 30 in the ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3NYU research looks to combat US Latina immigrant obesity 2Stanford professor finds that wildfires and other burns play bigger role in climate change 2Stanford professor finds that wildfires and other burns play bigger role in climate change 3Stanford professor finds that wildfires and other burns play bigger role in climate change 4
... are important vehicles for the transmission of enteric ... including human pathogens, are particularly abundant in bivalve ... procedures, thus representing a potential risk for human ... to affect the persistence of vibrios in these ...
... population of North Pacific right whales, found during the summer ... whale populations in the world. Commercial whaling in the 1800s ... these whales have been recognized as a different species from ... the Southern Hemisphere. , To help define areas and ecological ...
... in northern China starting as far back as 2400 ... farming combined with other crops, says University of Toronto ... with Chinese agriculture, most archeologists have, until recently, thought ... food associated with northern China. However, recent archeological research ...
Cached Biology News:Edible bivalves as a source of human pathogens: signals between vibrios and the bivalve host. 2Habitat use by North Pacific right whales, Eubalaena japonica, in the Bering Sea and Gulf of Alaska 2
Ubiquitin Related I Sampler Kit 10 mu g each...
Chaperone Sampler Kit 10 mu g each...
Zonula Adherens Sampler Kit 10 mu g each...
Tumor Suppressor Sampler Kit 10 mu g each...
Biology Products: